The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
Open accessAbstract
BACKGROUND: A single, high priming dose of tremelimumab (anti-cytotoxic T lymphocyte–associated antigen 4) plus durvalumab (anti–programmed cell death ligand-1), an infusion regimen termed STRIDE (Single Tremelimumab Regular Interval Durvalumab), showed encouraging clinical activity and safety in a phase 2 trial of unresectable hepatocellular carcinoma. METHODS: In this global, open-label, phase 3 trial, the majority of the patients we enrolled with unresectable hepatocellular carcinoma and no previous systemic treatment were randomly assigned to receive one of three regimens: tremelimumab (300 mg, one dose) plus durvalumab (1500 mg every 4 weeks; STRIDE), durvalumab (1500 mg every 4 weeks), or sorafenib (400 mg twice daily). The primary objective was overall survival for STRIDE versus sorafenib. Noninferiority for overall survival for durvalumab versus sorafenib was a secondary objective. RESULTS: In total, 1171 patients were randomly assigned to STRIDE (n=393), durvalumab (n=389), or sorafenib (n=389). The median overall survival was 16.43 months (95% confidence interval [CI], 14.16 to 19.58) with STRIDE, 16.56 months (95% CI, 14.06 to 19.12) with durvalumab, and 13.77 months (95% CI, 12.25 to 16.13) with sorafenib. Overall survival at 36 months was 30.7%, 24.7%, and 20.2%, respectively. The overall survival hazard ratio for STRIDE versus sorafenib was 0.78 (96.02% CI, 0.65 to 0.93; P=0.0035). Overall survival with durvalumab monotherapy was noninferior to sorafenib (hazard ratio, 0.86; 95.67% CI, 0.73 to 1.03; noninferiority margin, 1.08). Median progression-free survival was not significantly different among all three groups. Grade 3/4 treatment-emergent adverse events occurred for 50.5% of patients with STRIDE, 37.1% with durvalumab, and 52.4% with sorafenib. CONCLUSIONS: STRIDE significantly improved overall survival versus sorafenib. Durvalumab monotherapy was noninferior to sorafenib for patients with unresectable hepatocellular carcinoma. (Funded by AstraZeneca; ClinicalTrials.gov number, NCT03298451.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The response rate was 20% with durvalumab plus tremelimumab and 30% with atezolizumab plus bevacizumab, with median duration of response ranging from 18 months to 22 months.”
From Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial (2025) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“PD-L1 inhibitor-based regimens received approvals in 2020 (atezolizumab plus bevacizumab) and 2022 (tremelimumab plus durvalumab) as first-line treatment options for unresectable hepatocellular carcinoma after showing improved outcomes over sorafenib, with median overall survival ranging from 16 months to 19 months.”
From Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial (2025) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“With the introduction of PD-L1 inhibitors in this setting, survival benefits versus sorafenib were improved with a median overall survival of 19•2 months with atezolizumab plus bevacizumab, 9,10 16•6 months with durvalumab monotherapy, and 16•4 months with tremelimumab plus durvalumab, 7,8 leading to regulatory”
From Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial (2025) · cites this paper as [7]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“At the RP2D, the safety profile was consistent with the known safety profile of durvalumab in combination with tremelimumab in adult patients (13, 14), and no new safety signals were identified in our pediatric population.”
From Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors (2026) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“durvalumab plus tremelimumab has demonstrated improved OS compared with sorafenib alone in adults with unresectable hepatocellular cancer (14).”
From Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors (2026) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“In HIMALAYA, durvalumab plus tremelimumab yielded an objective response rate of 20% and median duration of response of 22•3 months.7”
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“up to 20% of OBIs may be negative for both HBsAg and hepatitis B core antibody (anti-HBc) with existing assays [67, 68]”
From Etiology-Based Treatment for Unresectable/Advanced Hepatocellular Carcinoma: Focus on Viral Hepatitis and Metabolic Dysfunction-Associated Steatohepatitis (2025) · cites this paper as [68]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Self-citationEASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Self-citationCombined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Self-citationOncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Kudo, M., Finn, R. S., Qin, S., Han, K.-H., Ikeda, K., Piscaglia, F., Baron, A., Park, J.-W., Han, G., Jassem, J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30207-1 · Cited by 5,497
Self-citationSchadendorf, D., Hodi, F. S., Robert, C., Weber, J. S., Margolin, K., Hamid, O., Patt, D., Chen, T.-T., Berman, D. M., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2736 · Cited by 2,141
Flagged first, then by citations
Cited by
Sorted by citations
Items 401–500 of 1,001
Oh, D., Rokutanda, N., Żotkiewicz, M., He, P., Stocks, J. D., & Johnson, M. L. (2024) · Targeted Oncology · doi:10.1007/s11523-024-01108-2 · Cited by 13
“…checkpoint inhibitors (ICIs) have transformed the treatment landscape across multiple tumor types [1–5] and many agents, including anti-programmed cell death (ligand)-1 (anti-PD-[L]1) inhibitors, and have demonstrated durable clinical activity both as monotherapy and combination therapy [4–8].”
Self-citationHepatocellular carcinoma systemic treatment update: From early to advanced stage
Teng, W., Wu, T.-C., & Lin, S. (2024) · Biomedical Journal · doi:10.1016/j.bj.2024.100815 · Cited by 14
Sui, M., Liu, T., Song, X., Li, J., Ding, H., Liu, Y., Wang, X., Liu, H., Xue, Y., Qi, J., et al. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107619 · Cited by 12
Pharmacological Profile of Novel Anti-cancer Drugs Approved by USFDA in 2022: A Review
Sangwan, K., Sharma, V., & Goyal, P. K. (2023) · Current Molecular Medicine · doi:10.2174/1566524023666230622151034 · Cited by 12
New Opportunities to Individualize Frontline Therapy in Advanced Stages of Hepatocellular Carcinoma
Gordan, J. D., Keenan, B. P., Lim, H. C., Yarchoan, M. M., & Kelley, R. K. (2023) · Drugs · doi:10.1007/s40265-023-01907-3 · Cited by 12
Self-citationKumar, R. N., Kim, J., Deek, M. P., Eskander, M. F., Gulhati, P., In, H., Kennedy, T. J., Shah, M. M., Grandhi, M. S., Berim, L. D., et al. (2023) · Current Oncology · doi:10.3390/curroncol30070473 · Cited by 11
Copil, F., Campani, C., Lequoy, M., Sultanik, P., Blaise, L., Wagner, M., Ganne‐Carrié, N., Ozenne, V., Thabut, D., Nault, J., et al. (2024) · Liver International · doi:10.1111/liv.15833 · Cited by 12
Immunotherapy for hepatobiliary malignancies: Progress and prospective
Qin, L. (2022) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2022.09.002 · Cited by 12
Epigenetic mechanisms in HCC immune landscape: Therapeutic implications
Fernández‐Barrena, M. G., Uriarte, I., Sarobe, P., & Avila, M. A. (2025) · Seminars in Immunology · doi:10.1016/j.smim.2025.101980 · Cited by 14
Cheng, Y., Zhou, Q., Han, B., Fan, Y., Li, S., Chang, J., Sun, S., Fang, J., Chen, Y., Sun, J., et al. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.01.013 · Cited by 11
Park, J., Lee, Y. B., Ko, Y., Park, Y., Shin, H., Hur, M. H., Park, M. K., Lee, D., Cho, E. J., Lee, K.-H., et al. (2024) · Journal of Liver Cancer · doi:10.17998/jlc.2023.12.25 · Cited by 11
Systemic therapies in hepatocellular carcinoma: A revolution?
Fortuny, M., Sanduzzi‐Zamparelli, M., & Reig, M. (2024) · United European Gastroenterology Journal · doi:10.1002/ueg2.12510 · Cited by 10
“It is interesting to observe that in the control arm of IMbrave150 20 and HIMALAYA, 17 where patients were treated with sorafenib and the OR rates (ORRs) were 11.9% and 5.1%, respectively.”
BackgroundMethodInfluentialGu, J., Yu, Z., Tang, X., Chen, W., Deng, X., & Zhu, X. (2024) · International Journal of Hyperthermia · doi:10.1080/02656736.2024.2373319 · Cited by 11
Liu, J., Xia, S., Zhang, B., Mohammed, D. M., Yang, X., Zhu, Y., & Jiang, X. (2024) · Discover Oncology · doi:10.1007/s12672-024-01110-0 · Cited by 11
“Median PFS was not signigicantly different among the three groups [139].”
BackgroundBae, S. H., Jang, W. I., Mortensen, H. R., Weber, B., Kim, M., & Høyer, M. (2024) · Journal of Liver Cancer · doi:10.17998/jlc.2024.06.26 · Cited by 11
Nakazawa, M., Fang, M., Vong, T., Zorzi, J., Griffith, P., Anders, R. A., Oshima, K., Kim, A. K., Laurin, J. M., Lafaro, K. J., et al. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0151 · Cited by 11
Yuan, G., Chen, Y., Zhu, P., Deng, Q., Su, K., Liu, J., Wang, Y., Li, R., Li, W., Zang, M., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e37616 · Cited by 12
“Combinations of CTLA-4 and PD-(L)1 inhibitors have demonstrated additive antitumor activity along with complementary immunostimulatory effects in HIMALAYA and Checkmate-040 studies [7,8].”
BackgroundInflammation and Immunity in Liver Neoplasms: Implications for Future Therapeutic Strategies
Kim, J., & Seki, E. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0726 · Cited by 11
Finn, R. S., Gu, K., Chen, X., Merle, P., Lee, K.-H., Bouattour, M., Cao, P., Wang, W., Cheng, A., Zhu, L., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101350 · Cited by 11
Self-citationDiagnosis, clinical characteristics, and treatment of combined hepatocellular-cholangiocarcinoma
Terashima, T., Harada, K., & Yamashita, T. (2025) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyaf029 · Cited by 11
PD-1/PD-L1 blockade therapy in hepatocellular carcinoma: Current status and potential biomarkers
Xu, P., Hong, C., Liu, L., & Xiao, L. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189334 · Cited by 12
Mohamed, N. M., Mohamed, R. H., Kennedy, J. F., ElHefnawi, M., & Hamdy, N. Μ. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.143616 · Cited by 15
Zavareh, M. S. R., Hwang, S. Y., Kim, N., Adetyan, H., Tran, N. H., & Yang, J. D. (2025) · Discover Oncology · doi:10.1007/s12672-025-03226-3 · Cited by 11
“So far, three combination regimens including ICIs, atezolizumab with bevacizumab [90], durvalumab with tremelimumab [91], and nivolumab with ipilimumab [92] have been approved as first line-treatment for advanced HCC treatment.”
Allaire, M., da Fonseca, L. G., Sanduzzi‐Zamparelli, M., Choi, W., Monge, C., Liu, K., Leibfried, M., Manes, S., Maravic, Z., Mishkovikj, M., et al. (2025) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2025.101408 · Cited by 12
Self-citationMehta, N. J., Kelley, R. K., & Yao, F. Y. (2023) · Hepatology · doi:10.1097/hep.0000000000000452 · Cited by 11
“[58,61] ICI combinations that include anti-CTLA-4 monoclonal antibodies, generally incur higher rates of immune-related toxicity, which is dose related.”
BackgroundMethodInfluentialSelf-citationAdvanced therapeutics avenues in hepatocellular carcinoma: a novel paradigm
Javed, & Yadav, S. (2023) · Medical Oncology · doi:10.1007/s12032-023-02104-8 · Cited by 11
Hatanaka, T., Kakizaki, S., Hiraoka, A., Tada, T., Hirooka, M., Kariyama, K., Tani, J., Atsukawa, M., Takaguchi, K., Itobayashi, E., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.6726 · Cited by 11
Self-citationChinese Expert Consensus on the Whole-Course Management of Hepatocellular Carcinoma (2023 Edition)
Yu, Y., Sun, J., Cai, J., Chen, M., Dai, C., Wen, T., Xia, J., Ying, M., Zhang, Z., Zhang, X., et al. (2024) · Liver Cancer · doi:10.1159/000541622 · Cited by 13
“The HIMALAYA study [37] also showed that durvalumab was non-inferior to sorafenib in terms of mOS (16.56 vs. 13.77 months, HR = 0.86; 96% CI = 0.73 – 1.03) with better safety ( ≥ grade 3 TRAEs: 12.9% vs. 36.9%).”
InfluentialGut microbiome, a novel precision medicine biomarker for hepatocellular carcinoma
Chen, P., Devkota, S., Shiao, S. L., Hendifar, A. E., & Yang, J. D. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1568962 · Cited by 12
“Atezolizumab plus bevacizumab and tremelimumab plus durvalumab are approved as standard-of-care for advanced HCC patients in the fi rst line setting (9, 10).”
Gastrointestinal cancer: molecular pathogenesis and targeted therapy
Jin, Y., He, X., & Wu, Y. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00361-9 · Cited by 13
Immunotherapy for virus-related hepatocellular carcinoma: recent progress and future directions
Song, R., Li, M., Tang, S., & Zhang, G. (2025) · Annals of Medicine · doi:10.1080/07853890.2025.2607229 · Cited by 11
“The 4-year OS rate was notably higher at 25.2% compared with 15.2% in the sorafenib arm [38].”
InfluentialBalcar, L., Bauer, D. J. M., Pomej, K., Meischl, T., Mandorfer, M., Reiberger, T., Trauner, M. A., Scheiner, B., & Pinter, M. (2023) · PLoS ONE · doi:10.1371/journal.pone.0282680 · Cited by 10
“The dual ICI regimen of durvalumab and tremelimumab is expected to be approved shortly as an alternative in first-line [3], after having improved its primary endpoint overall survival (OS) versus sorafenib in a phase III trial [5].”
BackgroundAdjuvant and Neoadjuvant Treatments for Resectable Hepatocellular Carcinoma
Crook, C. J., & Li, D. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01455-9 · Cited by 11
S3-Leitlinie „Diagnostik und Therapie des Hepatozellulären Karzinoms“ – Langversion 4.0
Bitzer, M., Groß, S., Albert, J., Blödt, S., Boda‐Heggemann, J., Brunner, T. B., Caspari, R., Toni, E. D., Dombrowski, F., Evert, M., et al. (2024) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2189-6353 · Cited by 10
Self-citationMuramatsu, J., Arihara, Y., Yoshida, M., Kubo, T., Nakamura, H., Ishikawa, K., Fujita, H., Sugita, S., Konno, T., Kojima, T., et al. (2024) · Cancer Science · doi:10.1111/cas.16101 · Cited by 8
Himmelsbach, V., Koch, C., Trojan, J., & Finkelmeier, F. (2024) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s443218 · Cited by 10
“12,13,18,33 Even in patients who manifested immune-related adverse events under the first ICI-based regimen, there was adequate safety under the second ICI regimen.”
BackgroundPersano, M., Rimini, M., Tada, T., Suda, G., Shimose, S., Kudo, M., Rossari, F., Yoo, C., Cheon, J., Finkelmeier, F., et al. (2024) · Targeted Oncology · doi:10.1007/s11523-024-01061-0 · Cited by 11
“This combination comprises a single dose of tremelimumab (anti-cytotoxic T-lymphocyte antigen 4) with another anti-PD-L1, durvalumab, and it achieved a median OS of 16.4 months [6].”
InfluentialSelf-citationRecent Advances in Liver Transplantation for Hepatocellular Carcinoma
Li, P. J., Shah, S., & Mehta, N. J. (2024) · Current Treatment Options in Oncology · doi:10.1007/s11864-024-01247-8 · Cited by 11
Rethinking Immune Check Point Inhibitors Use in Liver Transplantation: Implications and Resistance
Ortiz, V., & Loeuillard, E. J. (2024) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2024.101407 · Cited by 11
Fujii, Y., Kawaoka, T., Shirane, Y., Miura, R., Nakahara, H., Yamaoka, K., Uchikawa, S., Fujino, H., Ono, A., Murakami, E., et al. (2024) · Oncology · doi:10.1159/000542517 · Cited by 10
“Recently, the phase III HIMALAYA trial demonstrated the superiority of durvalumab (anti-PD-L1 inhibitor) and tremelimumab (anti-CTLA-4 inhibitor) combination therapy (STRIDE regimen) over sorafenib [1], establishing a new fi rst-line option for unresectable hepatocellular carcinoma (uHCC).”
Simultaneous Activation of Beta‐Oxidation and De Novo Lipogenesis in MASLD‐HCC: A New Paradigm
Dahboul, F., Sun, J.-H., Buchard, B., Abeywickrama-Samarakoon, N., Pujos-Guillot, E., Durand, S., Pétéra, M., Centeno, D., Guerrieri, F., Cocca, M., et al. (2025) · Liver international (Print) · doi:10.1111/liv.70006 · Cited by 10
“It has been reported that immunotherapy with ICIs was effective in VIRUS-HCC but provided little benefit in MASLD-HCC [32–34].”
Irizato, M., Minamiguchi, K., Uchiyama, T., Kunichika, H., Tachiiri, T., Taiji, R., Kitao, A., Marugami, N., Inaba, Y., & Tanaka, T. (2025) · Radiographics · doi:10.1148/rg.240068 · Cited by 10
Shimose, S., Saeki, I., Ito, T., Takeuchi, Y., Tani, J., Tomonari, T., Sasaki, R., Sasaki, K., Kakizaki, S., Hatanaka, T., et al. (2025) · Hepatology International · doi:10.1007/s12072-025-10781-y · Cited by 10
Llópiz, D., Silva, L., Ruiz, M., Castro-Alejos, C., Aparicio, B., Vegas, L., Infante, S., Santamaría, E., & Sarobe, P. (2025) · OncoImmunology · doi:10.1080/2162402x.2025.2473165 · Cited by 12
Chivite‐Lacaba, M., Justo, I., Utrero‐Rico, A., Caso, Ó., González‐Cuadrado, C., Rey, M. J. D., Laguna‐Goya, R., Arroyo‐Ródenas, J., Alfocea‐Molina, Á., Ruigómez‐Martín, C. C., et al. (2025) · International Journal of Cancer · doi:10.1002/ijc.35390 · Cited by 10
“10,11 These results further suggest that the elimination of MDSC would potentiate the anti-tumoral immunity in HCC and may provide therapeutic benefit.”
Shao, Y., Chen, C.-T., Chuang, C.-H., Su, T., Ho, M., Tseng, T., Liu, T., Wu, T., Cheng, A., & Hsu, C. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-02978-7 · Cited by 10
Self-citationGermline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse events
Middha, P., Thummalapalli, R., Quandt, Z., Balaratnam, K., Cardenas, E. R., Falcon, C. J., Princess Margaret Lung Group, Gubens, M. A., Huntsman, S., Khan, K., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-011273 · Cited by 12
“Analyses were conducted using PLINK, R V.4.2.3 (R Foundation for Statistical Computing), and all p values were two-sided.”
InfluentialSuzuki, T., Matsuura, K., Sobue, S., Kato, D., Hayashi, K., Kondo, H., Anbe, K., Mizoshita, T., Okayama, K., Okumura, F., et al. (2025) · Hepatology Research · doi:10.1111/hepr.14189 · Cited by 10
“After establishing combination therapy with atezolizumab and bevacizumab (Atez/Bev) for u - HCC, 9 dual ICI therapy with combination durvalumab and tremelimumab (Dur/Tre) was recently approved as a first - line treatment for u - HCC. 10 It has previously been reported that an early decline in tumor markers, such as α-…”
InfluentialKhaled, N. B., Zarka, V., Hobeika, B., Schneider, J. A., Rau, M., Weich, A., Leicht, H. B., Ye, L., Piseddu, I., Dill, M. T., et al. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70090 · Cited by 10
Jiang, J., Feng, K., Zhang, L., & Ma, K. (2025) · Oncology and Translational Medicine · doi:10.1097/ot9.0000000000000086 · Cited by 10
Manfredi, G. F., Fulgenzi, C. A. M., Celsa, C., Stefanini, B., D’Alessio, A., Pinter, M., Scheiner, B., Awosika, N. O., Brunetti, L., Lombardi, P., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101431 · Cited by 10
Self-citationYang, C., Zhang, M., Yao, Y., Wang, M., Zhong, X., Chen, Z., & Zhang, F. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1657398 · Cited by 10
Ding, Z., Meng, G.-X., Xue, J.-S., Liu, H., Yang, L.-S., Li, R., Mao, X., Yan, Y., Wang, D., Dong, Z., et al. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.103940 · Cited by 10
Jin, S. J., Choi, W., Shim, J. H., Lee, D., Kim, K. M., Lim, Y., Lee, H. C., Jung, J., Yoon, S. M., & Choi, J. (2023) · Journal of Liver Cancer · doi:10.17998/jlc.2023.03.04 · Cited by 10
“12,13 In these trials, HCC with MVI had a poor outcome compared with HCC without MVI, even at the same stage, in other words, BCLC stage C.”
Considerations for individualized first-line systemic treatment in advanced hepatocellular carcinoma
Peeters, F., & Dekervel, J. (2023) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2023.102365 · Cited by 9
Brazilian Landscape of Hepatocellular Carcinoma
da Fonseca, L. G., Chen, A. T. C., Oliveira, I. S., Chagas, A. L., Krüger, J. A. P., & Carrilho, F. J. (2023) · JCO Global Oncology · doi:10.1200/go.22.00416 · Cited by 10
Novel Molecular Targets for Immune Surveillance of Hepatocellular Carcinoma
Guerra, P., Martini, A., Pontisso, P., & Angeli, P. (2023) · Cancers · doi:10.3390/cancers15143629 · Cited by 11
“More recently, according to the results of the HIMALAYA trial, the association of Tremelimumab, an anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) monoclonal antibody, and Durvalumab (anti-PD-L1 monoclonal antibody) have been added to the possible first-line strategy of systemic therapy [27].”
BackgroundCammarota, A., Zanuso, V., Pressiani, T., Personeni, N., & Rimassa, L. (2022) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s268293 · Cited by 10
“More recently, the combination of a single priming dose of tremelimumab, an anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) mAb, plus durvalumab, an anti-PD-L1 mAb (STRIDE regimen) led to a significant overall survival (OS) advantage over sorafenib in the phase 3 HIMALAYA trial.(17) Of note, single-agent durvalumab was…”
BackgroundResultInfluentialSelf-citationHatanaka, T., Naganuma, A., Yata, Y., & Kakizaki, S. (2022) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-22-510 · Cited by 9
“The combination of atezolizumab with bevacizumab (IMbrave150) (2) and that of tremelimumab with durvalumab (HIMALAYA trial) (3) have achieved positive results in phase 3 trials in comparison to treatment with sorafenib.”
MethodResultOcaña‐Guzmán, R., Osorio-Pérez, D., & Chávez‐Galán, L. (2023) · Pharmaceuticals · doi:10.3390/ph16081119 · Cited by 9
“Nivolumab PD-1 Human IgG4, anti-PD-1 [39–41] Pembrolizumab PD-1 Humanized IgG4, anti-PD-1 [37,42–44] Atezolizumab PD-L1 Humanized IgG1, anti-PD-L1 [45–47] Cemiplimab PD-1 Human IgG4, anti-PD-1 [48,49] Ipilimumab CTLA-4 Human IgG1, anti-CTLA-4 [8,50,51] Avelumab PD-L1 Human IgG1 anti-PD-L1 [52–55] Durvalumab PD-L1 Huma…”
Tamura, Y., Ono, A., Nakahara, H., Hayes, C. N., Fujii, Y., Zhang, P., Yamauchi, M., Uchikawa, S., Teraoka, Y., Uchida, T., et al. (2023) · Cancers · doi:10.3390/cancers15174234 · Cited by 9
Chen, J., Jin, Z., Luo, B., Wang, Y.-Q., Li, R., Zhu, H., & Teng, G. (2023) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2023.00188 · Cited by 9
IMbrave050: the first step towards adjuvant therapy in hepatocellular carcinoma
Vogel, A., Meyer, T., & Saborowski, A. L. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01962-1 · Cited by 9
Shin, S., Moon, J., Oum, C., Kim, S., Cho, S. I., Lim, Y., Ock, C.-Y., & Shin, S. (2024) · BMC Cancer · doi:10.1186/s12885-024-11897-4 · Cited by 10
Finn, R. S., Qin, S., Piscaglia, F., Evans, T. R. J., Knox, J. J., López, C., Ramji, Z., Ren, M., Mody, K., Vogel, A., et al. (2024) · Liver Cancer · doi:10.1159/000537947 · Cited by 10
Self-citationAn, S., Li, W., Do, H., Kwon, H. Y., Kim, B., Kim, K., Kim, Y. W., & Cho, M.-Y. (2024) · Biomedicines · doi:10.3390/biomedicines12040752 · Cited by 9
Wu, X.-H., Wang, J.-Q., Wang, M.-D., Xiao, T., Wang, Y., Niu, J.-Y., Wang, L., Hou, D.-Y., Fu, B., Liu, Z., et al. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122550 · Cited by 9
Kim, Y., Kim, J. S., Kang, B., Kim, I. H., Kim, H., Lee, W. S., Sang, Y. B., Jung, S., An, C., Kim, C., et al. (2024) · Cancer Research and Treatment · doi:10.4143/crt.2024.237 · Cited by 9
“The STRIDE regimen (tremelimumab plus dur-valumab) [27,28] had little effect on liver function deterioration during long-term treatment, suggesting that, unlike dual immunotherapy, long-term immunotherapy combined with an anti-angiogenic agent may affect liver function.”
Saleh, Y., Hejleh, T. A., Abdelrahim, M., Shamseddine, A. I., Chehade, L., Alawabdeh, T., Mohamad, I., Sammour, M., & Turfa, R. (2024) · Cancers · doi:10.3390/cancers16112081 · Cited by 10
“Similarly, in the HIMALAYA trial, treatment with durvalumab and tremelimumab showed OS benefit compared to durvalumab or sorafenib as single agents in advanced HCC regardless of the PD-L1 expression [53].”
Fong, C., Patel, B., Peckitt, C., Bourmpaki, E., Satchwell, L., Cromarty, S., Kidd, S., von Loga, K., Uhlik, M. T., Begum, R., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103622 · Cited by 9
Matar, A. J., Oppat, K. M., Bennett, F. J., Warren, E. A. K., Wehrle, C. J., Li, Z., Rajendran, L., Rokop, Z. P., Kubal, C. A., Biesterveld, B. E., et al. (2024) · Annals of Surgical Oncology · doi:10.1245/s10434-024-16085-z · Cited by 8
Tamaki, N., Mori, N., Takaki, S., Tsuji, K., Tada, T., Nakamura, S., Ochi, H., Mashiba, T., Doisaki, M., Marusawa, H., et al. (2024) · Anticancer Research · doi:10.21873/anticanres.17219 · Cited by 9
Kuwano, A., TANAKA, K., Takahira, J., Suzuki, H., Ohishi, Y., & Motomura, K. (2024) · In Vivo · doi:10.21873/invivo.13757 · Cited by 10
Hepatotoxicity in Cancer Immunotherapy: Diagnosis, Management, and Future Perspectives
Savino, A., Rossi, A., FAGIUOLI, S., Invernizzi, P., Gerussi, A., & Viganò, M. (2024) · Cancers · doi:10.3390/cancers17010076 · Cited by 9
Cillo, U., Gringeri, E., D’Amico, F. E., Lanari, J., Furlanetto, A., & Vitale, A. (2025) · Digestive and Liver Disease · doi:10.1016/j.dld.2024.12.003 · Cited by 9
Serum FGF21 as a predictor of response to atezolizumab and bevacizumab in HCC
Kohya, R., Suda, G., Ohara, M., Hosoda, S., Sho, T., Chuma, M., Komori, A., Kugiyama, Y., Yasui, Y., Tsuchiya, K., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101364 · Cited by 9
Myeloid cell path to malignancy: insights into liver cancer
Ramirez, C. F. A., & Akkari, L. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.02.006 · Cited by 11
Jayabalan, D., Dhakal, S., Raguragavan, A., Saxena, A., Jeffrey, G. P., Bertot, L. C., Adams, L. A., & Wallace, M. C. (2025) · International Journal of Hepatology · doi:10.1155/ijh/1083642 · Cited by 11
“Abou-Alfa et al. found sorafenib to have a worse time TTD in HRQOL compared to durvalumab and single tremelimumab regular interval durvalumab (STRIDE) [53].”
Piñero, F., Anders, M., Bermúdez, C., Arufe, D., Varón, A., Palazzo, A., Rodriguez, J., Beltrán, O., Simian, D., da Fonseca, L. G., et al. (2025) · Liver International · doi:10.1111/liv.70092 · Cited by 9
“Subsequently, other ICIs or dual-ICIs regimens, such as durvalumab (anti- PD-L1) plus tremelimumab, a cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody, have also shown a survival benefit over sorafenib [6–8].”
Morgan, C., Kurland, J. F., Patel, M., O’Brien, C., Concepcion, P., Doherty, G. J., Hois, S., Negro, A., Pavlović, D., & Robbins, K. A. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-011140 · Cited by 9
Self-citationPrinzi, F. L., Rossari, F., Silletta, M., Camera, S., Foti, S., Persano, M., Vitiello, F., Giacomo, E. D., Polito, M. G., Rimini, M., et al. (2025) · Targeted Oncology · doi:10.1007/s11523-025-01161-5 · Cited by 9
“The indirect comparison by Fulgenzi et al. [18], who conducted a network meta-analysis of nine phase 3 studies, included SHARP [4], Asia Pacific [5], REFLECT [6], Check-Mate 459 [14], IMbrave150 [8, 9], ORIENT-32 [15], Himalaya [10, 11], COSMIC-312 [16], and the study by Qin et al. [17].”
InfluentialHatanaka, T., Yata, Y., Hiraoka, A., Tada, T., Hirooka, M., Kariyama, K., Tani, J., Atsukawa, M., Takaguchi, K., Itobayashi, E., et al. (2025) · Liver International · doi:10.1111/liv.70192 · Cited by 9
Self-citationPamungkas, K. M. N., Dewi, P. I. S. L., Alamsyah, A. Z., Dewi, N. L. P. Y., Dewi, N. N. G. K., Mariadi, I. K., & Sindhughosa, D. A. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i7.106810 · Cited by 11
Lee, I., Wang, H.-W., Teng, W., Lin, T., Chen, C.-H., Lai, H., Lee, T., Chang, C.-W., Hung, C., Dai, C., et al. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0724 · Cited by 11
Dayhimi, A., Jazi, K., Bigdeli, Y., Farhoudi, F., Erfanimanesh, M., Esmaeili, M., Gorjipour, F., Ajami, M., & Pazoki–Toroudi, H. (2025) · Technology in Cancer Research & Treatment · doi:10.1177/15330338251365700 · Cited by 11
Chen, Y., Chen, D., Liang, Z., Yu, H., Sun, H., Hu, Y., Jiang, P., Zhang, M., Ye, L., & Li, H. (2025) · Cancer Drug Resistance · doi:10.20517/cdr.2025.120 · Cited by 9
Mesropian, A., Gris‐Oliver, A., Balaseviciute, U., Potdar, A. A., Kimura, T., Shen, J., Torres-Marcén, M., Abril‐Fornaguera, J., Piqué‐Gili, M., Camell-Raventos, D., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-0725 · Cited by 10
Self-citationAkabane, M., Imaoka, Y., Lee, G. R., & Pawlik, T. (2025) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2025.2568904 · Cited by 10
Navigating second-line therapy after immunotherapy in advanced HCC☆
Vogel, A., Saborowski, A. L., Rimassa, L., & El-Khoueiry, A. B. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101630 · Cited by 9
“7,8,10 Prior to being tested in first line, nivolumab and ipilimumab showed remarkable activity in patients with advanced HCC who were previously treated with sorafenib in the phase I/II CheckMate 040 trial.”
Self-citationPonziani, F. R., Giannelli, V., Marrone, G., Martini, S., Morelli, M. C., Pagano, D., Svegliati‐Baroni, G., Germani, G., Burra, P., & Toniutto, P. (2026) · American Journal of Transplantation · doi:10.1016/j.ajt.2026.02.024 · Cited by 9
Hwang, M., Chia, Y. L., Zheng, Y., Chen, C. C., He, Z., Song, X., Zhou, D., Goldberg, S. B., Siu, L. L., Planchard, D., et al. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15622 · Cited by 9
“These findings will be of importance for informing future dosing recommendations of durvalumab and tremelimumab in the context of the positive outcomes of Phase 3 clinical studies, such as POSEIDON(24) in metastatic non-small-cell lung cancer and HIMALAYA in hepatocellular carcinoma.(25)”
Fessas, P., Scheiner, B., D’Alessio, A., Fulgenzi, C. A. M., Korolewicz, J., Ward, C. E., Tait, P., Thomas, R., Cortellini, A., Sharma, R., et al. (2023) · Future Oncology · doi:10.2217/fon-2022-0916 · Cited by 9
Clinical Characterization of HCC/CCA Mixed Cancers in a Population-based Cohort
Teufel, A., Rodriguez, I., Winzler, C., Kokh, D., Ebert, M. P., Surovtsova, I., & Morakis, P. (2023) · Journal of Gastrointestinal and Liver Diseases · doi:10.15403/jgld-4893 · Cited by 9
“Moreover, the HIMALAYA trial evaluated tremelimumab (CTLA-4 inhibitor) plus durvalumab (PD-1 inhibitor) showing superiority against sorafenib in HCC patients and obtained approval [14].”
BackgroundImmunotherapy for Advanced Hepatocellular Carcinoma-a Large Tertiary Center Experience
Raj, R., Aykun, N., Wehrle, C. J., Maspero, M., Krishnamurthi, S., Estfan, B. N., Kamath, S. D., & Aucejo, F. (2023) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-023-05783-w · Cited by 9
“44 Several multikinase agents in patients who progressed on Atezo/Bev combination are also under investigation, however, there is lack of data reporting any trend of response or resistance in patients who received Atezo/Bev after failure with Sorafenib.”
Kanzaki, H., Ogasawara, S., Okubo, T., Itokawa, N., Yoshino, R., Fujimoto, K., Kogure, T., Yumita, S., Ishino, T., Ogawa, K., et al. (2023) · Drugs - Real World Outcomes · doi:10.1007/s40801-023-00379-x · Cited by 9
Nakamura, H., Shionoya, A., Arihara, Y., Hayasaka, N., Kubo, T., Usami, M., Sugita, S., Uhara, H., & Takada, K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1259071 · Cited by 10
Scheiner, B., Lampichler, K., Pomej, K., Beer, L., Balcar, L., Sartoris, R., Bouattour, M., Sidali, S., Trauner, M. A., Mandorfer, M., et al. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000261 · Cited by 9
“However, only up to one third of patients shows complete response (CR) or partial response (PR), and around 20%–40% of patients have primary resistance to PD-(L)1-based regimen.[7,8] Furthermore, no validated biomarker exists to predict response or resistance to ICIs in HCC or to guide patient selection for immunother…”
BackgroundLucas, A. P., Lewis, A. R., Kasi, P. M., Toskich, B. B., & Paz‐Fumagalli, R. (2023) · Radiology Case Reports · doi:10.1016/j.radcr.2023.11.062 · Cited by 9
“The phase III HIMALAYA trial found that a combination of tremelimumab and durvalumab had a 22% decrease in risk of death compared to sorafenib and is another first-line systemic therapy option [8] .”
BackgroundThe State of Systematic Therapies in Clinic for Hepatobiliary Cancers
Chen, W., Hu, Z., Li, G., Zhang, L., & Li, T. (2024) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s454666 · Cited by 10
She, M., Wu, Y., Cheng, M., Feng, S., Li, G., & Rong, H. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1401139 · Cited by 9
Metadata
- Authors
- Abou-Alfa, G. K., Lau, G., Kudo, M., Chan, S. L., Kelley, R. K., Furuse, J., Sukeepaisarnjaroen, W., Kang, Y.-K., Van Dao, T., De Toni, E. N., Rimassa, L., Breder, V., Vasilyev, A., Heurgué, A., Tam, V. C., Mody, K., Thungappa, S. C., Ostapenko, Y., Yau, T., Azevedo, S., Varela, M., Cheng, A.-L., Qin, S., Galle, P. R., Ali, S., Marcovitz, M., Makowsky, M., He, P., Kurland, J. F., Negro, A., & Sangro, B.
- Affiliations
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York
- Humanity & Health (CN)
- Kindai University Hospital (JP)
- Chinese University of Hong Kong (HK)
- University of California, San Francisco (US)
- Kyorin University (JP)
- Khon Kaen University (TH)
- Asan Medical Center (KR)
- Cancer Research and Clinical Trials Center, Department of Optimal Therapy, National Cancer Hospital, Hanoi, Vietnam
- Department of Medicine II, University Hospital, Ludwig Maximilian University Munich, Munich, Germany
- Humanitas University (IT)
- Russian Cancer Research Center NN Blokhin (RU)
- Department of Oncology, Railway Clinical Hospital, St. Petersburg, Russia
- Department of Hepato-Gastroenterology, Robert-Debré Hospital, Reims, France
- University of Calgary (CA)
- Mayo Clinic (US)
- Sri Venkateshwara Hospital, Bangalore, India
- National Cancer Institute (UA)
- Queen Mary Hospital (CN)
- Unidade de Pesquisa em Oncologia Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
- Liver Unit, Hospital Universitario Central de Asturias, Universidad de Oviedo, Instituto Universitario de Oncología del Principado de Asturias–Obra Social Cajastur, Instituto de Investigación Sanitaria del Principado de Asturias, Fundación para la Investigación y la Innovación Biosanitaria del Principado de Asturia, Oviedo, Spain
- National Taiwan University (TW)
- 81th Hospital of PLA (CN)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- AstraZeneca (United States) (US)
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (ES)
- ORCID
- Lau, George
- Kudo, Masatoshi
- Chan, Stephen L.
- Kelley, Robin Kate
- Furuse, Junji
- Sukeepaisarnjaroen, Wattana
- Kang, Yoon-Koo
- Rimassa, Lorenza
- Breder, Valeriy
- Heurgué, Alexandra
- Tam, Vincent C.
- Mody, Kabir
- Yau, Thomas
- Cheng, Ann-Lii
- Qin, Shukui
- Galle, Peter R.
- Marcovitz, Michelle
- He, Philip
- Kurland, John F.
- Negro, Alejandra
- Sangro, Bruno
- Venue
- NEJM Evidence
- Publisher
- Massachusetts Medical Society
- Published
- 2022-07-26
- Volume
- 1
- Issue
- 8
- Pages
- EVIDoa2100070-EVIDoa2100070
- ISSN
- 2766-5526 (ISSN-L)
- OpenAlex
- W4281645619
- Cited by
- 1,576
- References
- 23
- Citations by year
- 2026: 356 · 2025: 450 · 2024: 421 · 2023: 284 · 2022: 63
- FWCI
- 181.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- NEJM Evidence (publishedVersion)
- PubMed (publishedVersion)
- Funders
- AstraZeneca
- Topics
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
- Keywords
- tremelimumab, durvalumab, hepatocellular carcinoma, unresectable liver cancer, CTLA-4 blockade, PD-L1 blockade, sorafenib, overall survival, non-inferiority, immune checkpoint inhibitors, combination immunotherapy, progression-free survival, treatment-emergent adverse events, immune-related adverse events, non-small cell lung cancer
- MeSH terms
- Antineoplastic Agents, Immunological, Sorafenib, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Female, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Male, Middle Aged, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
